-
Acclaimed Iraqi film explores Saddam Hussein's absurd birthday rituals
-
On rare earth supply, Trump for once seeks allies
-
Ukrainian chasing sumo greatness after meteoric rise
-
Draper to make long-awaited return in Davis Cup qualifier
-
Can Ilia Malinin fulfil his promise at the Winter Olympics?
-
CK Hutchison begins arbitration against Panama over annulled canal contract
-
UNESCO recognition inspires hope in Afghan artist's city
-
Ukraine, Russia, US negotiators gather in Abu Dhabi for war talks
-
WTO must 'reform or die': talks facilitator
-
Doctors hope UK archive can solve under-50s bowel cancer mystery
-
Stocks swing following latest AI-fuelled sell-off on Wall St
-
Demanding Dupont set to fire France in Ireland opener
-
Britain's ex-prince Andrew leaves Windsor home: BBC
-
Coach plots first South Africa World Cup win after Test triumph
-
Spin-heavy Pakistan hit form, but India boycott risks early T20 exit
-
Japan eyes Premier League parity by aligning calendar with Europe
-
Whack-a-mole: US academic fights to purge his AI deepfakes
-
Love in a time of war for journalist and activist in new documentary
-
'Unprecedented mass killing': NGOs battle to quantify Iran crackdown scale
-
Seahawks kid Cooper Kupp seeks new Super Bowl memories
-
Thousands of Venezuelans march to demand Maduro's release
-
AI, manipulated images falsely link some US politicians with Epstein
-
Move on, says Trump as Epstein files trigger probe into British politician
-
Arteta backs Arsenal to build on 'magical' place in League Cup final
-
Evil Empire to underdogs: Patriots eye 7th Super Bowl
-
UBS grilled on Capitol Hill over Nazi-era probe
-
Guardiola 'hurt' by suffering caused in global conflicts
-
Marseille do their work early to beat Rennes in French Cup
-
Trump signs spending bill ending US government shutdown
-
Arsenal sink Chelsea to reach League Cup final
-
Leverkusen sink St Pauli to book spot in German Cup semis
-
'We just need something positive' - Monks' peace walk across US draws large crowds
-
Milan close gap on Inter with 3-0 win over Bologna
-
No US immigration agents at Super Bowl: security chief
-
NASA Moon mission launch delayed to March after test
-
Spain to seek social media ban for under-16s
-
LIV Golf events to receive world ranking points: official
-
US House passes spending bill ending government shutdown
-
US jet downs Iran drone but talks still on course
-
UK police launching criminal probe into ex-envoy Mandelson
-
US-Iran talks 'still scheduled' after drone shot down: White House
-
Chomsky sympathized with Epstein over 'horrible' press treatment
-
French prosecutors stick to demand for five-year ban for Le Pen
-
Russia's economic growth slowed to 1% in 2025: Putin
-
Bethell spins England to 3-0 sweep over Sri Lanka in World Cup warm-up
-
Nagelsmann backs Ter Stegen for World Cup despite 'cruel' injury
-
Homage or propaganda? Carnival parade stars Brazil's Lula
-
EU must be 'less naive' in COP climate talks: French ministry
-
Colombia's Petro meets Trump after months of tensions
-
Air India inspects Boeing 787 fuel switches after grounding
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
P.L.Madureira--PC